Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice

Int Immunol. 2001 Aug;13(8):975-82. doi: 10.1093/intimm/13.8.975.

Abstract

Prior to the activation of CD4 (+) T cells, exogenous proteins must be digested by endo/lysosomal enzymes in antigen-presenting cells (APC) to produce antigenic peptides that are able to be presented on class II molecules of the MHC. Studies described here inspect the functional significance of cathepsin L inhibition for antigen processing and T (h) 1/T (h) 2 differentiation in experimental leishmaniasis. We first demonstrated using in vitro systems that cathepsin L is one of the candidate endo/lysosomal enzymes in processing of soluble Leishmania antigen (SLA) and that its specific inhibitor, CLIK148, modulated the processing of SLA. BALB/c mice are known to be susceptible to infection with Leishmania major. Interestingly, treatment of BALB/c mice with CLIK148 exacerbated the infection by enhancing the development of SLA-specific T (h) 2-type response such as production of IL-4 and generation of T (h) 2-dependent specific IgE/IgG1 antibodies. Moreover, addition of CLIK148 in incubation of a SLA-specific CD4 (+) T cell line with APC up-regulated the production of IL-4. However, CLIK148 did not exert any direct influence on the function of T cells themselves. Taken together, these findings suggest that treatment of host mice with CLIK148 affects the processing of SLA in APC, resulting in the potentiation of T (h) 2-type immune responses and thus leading to exacerbation of the infection. Furthermore, endo/lysosomal cathepsin L was found to be functionally distinct from previously described cathepsins B and D.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Antigen Presentation / drug effects
  • Antigens, Protozoan / immunology
  • Antigens, Protozoan / metabolism
  • Cathepsin L
  • Cathepsins / antagonists & inhibitors*
  • Cell Differentiation / drug effects
  • Cell Differentiation / immunology
  • Cell Line
  • Cysteine Endopeptidases
  • Cysteine Proteinase Inhibitors / pharmacology*
  • Dipeptides / administration & dosage
  • Dipeptides / pharmacology
  • Endosomes / enzymology
  • Epoxy Compounds / administration & dosage
  • Epoxy Compounds / pharmacology*
  • Female
  • Injections, Intraperitoneal
  • Leishmania major / drug effects*
  • Leishmania major / immunology*
  • Leishmaniasis, Cutaneous / enzymology*
  • Leishmaniasis, Cutaneous / etiology
  • Leishmaniasis, Cutaneous / immunology*
  • Lysosomes / enzymology
  • Mice
  • Mice, Inbred BALB C
  • Pyridines / administration & dosage
  • Pyridines / pharmacology*
  • Solubility
  • Th2 Cells / cytology
  • Th2 Cells / drug effects
  • Th2 Cells / immunology*

Substances

  • Adjuvants, Immunologic
  • Antigens, Protozoan
  • CA 074 methyl ester
  • CLIK 148
  • Cysteine Proteinase Inhibitors
  • Dipeptides
  • Epoxy Compounds
  • Pyridines
  • Cathepsins
  • Cysteine Endopeptidases
  • Cathepsin L
  • Ctsl protein, mouse